Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL887785 | 0.81 | TSHR (0.30) | TSHR | |
| SCHEMBL2006115 | 0.78 | TSHR (0.32) | TSHR | |
| SCHEMBL8741525 | 0.77 | — | — | |
| SCHEMBL1059438 | 0.77 | — | — | |
| SCHEMBL2006417 | 0.73 | — | — | |
| SCHEMBL78637 | 0.72 | TSHR (0.35) | TSHR | |
| SCHEMBL9436377 | 0.72 | TSHR (0.35) | TSHR | |
| SCHEMBL25408699 | 0.71 | — | — | |
| SCHEMBL769365 | 0.71 | — | — | |
| SCHEMBL2384813 | 0.71 | TSHR (0.39) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2647713-B1 | MODIFIED SINGLE-STRAND POLYNUCLEOTIDE | DAIICHI SANKYO CO LTD (JP) | 2018-02-21 | — | — | EP | claimed |
| US-8987226-B2 | Modified single-stranded polynucleotides | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-03-24 | — | — | US | claimed |
| EP-2647713-A1 | MODIFIED SINGLE-STRAND POLYNUCLEOTIDE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-10-09 | — | — | EP | claimed |
| US-20130253038-A1 | Modified Single-Stranded Polynucleotide | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-09-26 | — | — | US | claimed |
| JP-4756863-B2 | — | — | 2011-08-24 | — | — | JP | claimed |
| US-7247720-B2 | Phosphitylation process | AVECIA BIOTECHNOLOGY INC. (US) | 2007-07-24 | — | — | US | claimed |
| EP-1554300-B1 | PHOSPHITYLATION PROCESS | AVECIA BIOTECHNOLOGY INC (US) | 2007-05-23 | — | — | EP | claimed |
| US-20060069247-A1 | Phosphitylation process | AVECIA BIOTECHNOLOGY INC. (US) | 2006-03-30 | — | — | US | claimed |
| EP-1554300-A1 | PHOSPHITYLATION PROCESS | Avecia Biotechnology, Inc. (US) | 2005-07-20 | — | — | EP | claimed |
| WO-2004035599-A1 | PHOSPHITYLATION PROCESS | AVECIA BIOTECHNOLOGY INC. (US) | 2004-04-29 | — | — | WO | claimed |
| JP-2011597-A | — | — | None | — | — | JP | disclosed |
| EP-4677084-A1 | MODIFIED SHORT INERFERING NUCLEIC ACID (SINA) MOLECULES AND USES THEREOF | Aligos Therapeutics, Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| EP-3765476-B1 | MODIFIED OLIGONUCLEOTIDES FOR USE IN TREATMENT OF TAUOPATHIES | JANSSEN PHARMACEUTICA NV (BE) | 2025-11-26 | — | — | EP | disclosed |
| EP-3402801-B1 | CYCLIC DINUCLEOTIDES FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY SUCH AS CANCER | INNATE TUMOR IMMUNITY INC (US) | 2025-08-06 | — | — | EP | disclosed |
| WO-2025063238-A1 | SIRNA FOR SUPPRESSING EXPRESSION OF PHOSPHOLAMBAN | 第一三共株式会社 | 2025-03-27 | — | — | WO | disclosed |
| US-5047524-A | Solid phase syntheisis o nonsuelladle porous polystyrene support by phosphoramide or hydrogen phosphonate chemistry | APPLIED BIOSYSTEMS, INC. (US) | 1991-09-10 | — | — | US | disclosed |
| EP-0422090-A1 | DERIVATIVES OF NUCLEOSIDES WHICH MAY BE USED FOR THE SYNTHESIS OF MARKED OLIGONUCLEOTIDES, AND OLIGONUCLEOTIDES OBTAINED FROM THESE DERIVATIVES AND THEIR SYNTHESIS. | CIS BIO INT (FR) | 1991-04-17 | — | — | EP | disclosed |
| EP-0375278-A2 | Automated system for polynucleotide synthesis and purification | THE PERKIN-ELMER CORPORATION (US) | 1990-06-27 | — | — | EP | disclosed |
| JP-H0211597-A | RUTHENIUM COMPOSITE COMPOUND CONTAINING DNA OR RNA SEQUENCE | F HOFFMANN LA ROCHE AG | 1990-01-16 | — | — | JP | disclosed |
| WO-1989012642-A1 | DERIVATIVES OF NUCLEOSIDES WHICH MAY BE USED FOR THE SYNTHESIS OF MARKED OLIGONUCLEOTIDES, AND OLIGONUCLEOTIDES OBTAINED FROM THESE DERIVATIVES AND THEIR SYNTHESIS | CIS BIO INTERNATIONAL (FR) | 1989-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069247-A1 | Phosphitylation process | PHOSPHO1, MTAP, PNP | TSHR 1849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.